OS Therapies Incorporated
OSTXHealthcare|Biotechnology|US
$1.00
+0.02 (+2.03%)
Cash / Share
$0.00
Financials
Financial Snapshot
Market Cap
$46.8M
Enterprise Value
$46.6M
Revenue (TTM)
$0.00
Net Income (TTM)
-$39.4M
Cash & Investments
$205.0K
Net Cash
$205.0K
Free Cash Flow (TTM)
-$18.5M
Operating CF (TTM)
-$18.5M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$205.0K
Quarterly Burn
$4.6M
Monthly Burn
$1.5M
Est. Runway
~0.0 quarters
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $1.23B | $80.8K | $171.5K | $39.0K | $5.5M | $269.8K | $205.0K | |
| Operating Cash Flow | -$2.41B | -$4.4M | -$3.8M | -$3.0M | -$7.3M | -$14.24B | -$18.5M | |
| Free Cash Flow | -$2.42B | -$4.4M | -$3.8M | -$3.0M | -$7.3M | -$14.24B | -$18.5M | |
| Capital Expenditure | -$2.0M | -$11.9K | $0.00 | $0.00 | $0.00 | -$466.4K | $0.00 | |
| Financing Cash Flow | $3.48B | $3.1M | $3.7M | $2.9M | $12.8M | $9.44B | $15.9M |
R&D Spending
R&D (TTM)
$22.44B
R&D Intensity
—
R&D Growth vs Prior
+37.1%
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $601.78 | $2.2M | $3.3M | $3.2M | $2.8M | $16.36B | $22.44B | |
| SG&A | $795.42 | $1.5M | $1.2M | $1.1M | $4.0M | $12.34B | $14.84B |
Income Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $4.3K | $1.2M | $805.00 | $4.2K | $2.8K | $363.1K | $374.8K | |
| Gross Profit | -$4.3K | -$1.2M | -$805.00 | -$4.2K | -$2.8K | -$363.1K | -$374.8K | |
| R&D | $601.78 | $2.2M | $3.3M | $3.2M | $2.8M | $16.36B | $22.44B | |
| SG&A | $795.42 | $1.5M | $1.2M | $1.1M | $4.0M | $12.34B | $14.84B | |
| Operating Income | -$5.6K | -$4.8M | -$4.4M | -$4.3M | -$6.8M | -$28.7M | -$37.6M | |
| Interest Expense | $461.8M | $2.6M | $1.8M | $3.4M | $2.1M | $0.00 | $80.9K | |
| Pretax Income | -$6.0K | -$7.4M | -$6.3M | -$7.8M | -$8.9M | -$28.8M | -$39.4M | |
| Net Income | -$6.0K | -$7.4M | -$6.3M | -$7.8M | -$8.9M | -$28.8M | -$39.4M | |
| EPS (Diluted) | -0.00 | -0.33 | -0.28 | -0.39 | -0.52 | -0.98 | -1.09 | |
| EBITDA | $61.4K | -$4.8M | -$4.4M | -$4.3M | -$6.8M | -$28.4M | -$38.7M | |
| Shares Out. (M) | 8.42 | 23.10 | 23.10 | 20.05 | 20.87 | 29.25 | 43.90 |
Balance Sheet
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.23B | $80.8K | $171.5K | $39.0K | $5.5M | $269.8K | $205.0K | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $1.68B | $312.8K | $496.8K | $790.0K | $5.5M | $332.9K | $3.6M | |
| Total Assets | $1.68B | $325.9K | $509.1K | $798.1K | $5.5M | $6.8M | $9.9M | |
| Total Current Liabilities | $2.10B | $3.5M | $6.1M | $24.7M | $4.6M | $11.8M | $20.6M | |
| Long-Term Debt | $5.90B | $7.1M | $10.3M | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $8.00B | $11.8M | $18.1M | $24.8M | $4.7M | $12.9M | $20.6M | |
| Stockholders' Equity | -$6.33B | -$11.5M | -$17.6M | -$24.0M | $811.5K | -$6.1M | -$10.8M | |
| Retained Earnings | -$6.34B | -$15.2M | -$21.6M | -$29.5M | -$40.4M | -$67.2M | -$86.2M |
Cash Flow Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.41B | -$4.4M | -$3.8M | -$3.0M | -$7.3M | -$14.24B | -$18.5M | |
| Capital Expenditure | -$2.0M | -$11.9K | $0.00 | $0.00 | $0.00 | -$466.4K | $0.00 | |
| Free Cash Flow | -$2.42B | -$4.4M | -$3.8M | -$3.0M | -$7.3M | -$14.24B | -$18.5M | |
| Investing Cash Flow | $158.3M | $200.5K | $230.9K | $1.1K | $0.00 | -$466.4M | $0.00 | |
| Financing Cash Flow | $3.48B | $3.1M | $3.7M | $2.9M | $12.8M | $9.44B | $15.9M | |
| Issuance of Stock | $2.1M | $0.00 | $0.00 | $0.00 | $5.2M | $8.4M | $7.8M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $3.48B | $3.0M | $3.8M | $3.2M | $1.5M | $0.00 | $1.8M | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $268.3K | $4.27B | $4.26B | |
| Net Change in Cash | $1.23B | -$1.2M | $90.7K | -$132.5K | $5.5M | -$5.26B | -$2.6M |
Dilution Tracker
Shares outstanding grew 247.3% over 5 years — significant dilution
Shares Outstanding
47M
5-Year Share Growth
+247.3%
Stock Issuance (TTM)
$7.8M
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 8.42 | 23.10 | 23.10 | 20.05 | 20.87 | 29.25 | 43.90 | |
| Change vs Prior % | — | 174.3% | 0.0% | -13.2% | 4.1% | 40.2% | 50.1% | |
| Stock Issuance | $2.1M | $0.00 | $0.00 | $0.00 | $5.2M | $8.4M | $7.8M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $268.3K | $4.27B | $4.26B |
Margins & Profitability
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| ROE % | 0.0% | 64.8% | 35.6% | 32.4% | -1094.6% | 471.7% | 683.0% | |
| ROA % | -0.0% | -2276.9% | -1228.6% | -976.3% | -160.4% | -420.4% | -397.8% | |
| ROIC % | -0.0% | 152.6% | 78.9% | 46.7% | -747.6% | 582.9% | 350.1% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | -27185.7% | 99.9% | -424.2% | 34.1% | -12960.6% | |
| Operating Income | 0.0% | -85562.4% | 8.1% | 2.3% | -56.9% | -321.3% | |
| Net Income | 0.0% | -123016.8% | 15.7% | -24.6% | -14.0% | -223.7% | |
| EPS (Diluted) | 0.0% | -47042.9% | 15.2% | -39.3% | -33.3% | -88.5% | |
| Operating Cash Flow | 0.0% | 99.8% | 13.9% | 20.7% | -142.2% | -195423.2% | |
| Free Cash Flow | 0.0% | 99.8% | 14.1% | 20.7% | -142.2% | -195423.2% | |
| R&D Expense | 0.0% | 361193.1% | 51.4% | -2.3% | -11.8% | 576737.4% | |
| SG&A Expense | 0.0% | 188923.0% | -23.3% | -2.9% | 254.7% | 310482.2% | |
| Total Assets | 0.0% | -100.0% | 56.2% | 56.8% | 594.0% | 23.5% | |
| Book Value / Share | 0.0% | 99.9% | -53.3% | -57.6% | 103.2% | -635.9% | |
| Debt | 0.0% | -99.9% | 46.3% | 41.2% | -100.0% | 0.0% | |
| Diluted Shares | 0.0% | 174.3% | 0.0% | -13.2% | 4.1% | 40.2% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B-4.05
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
Cash / Share
$0.00
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -3585.71 | -7.61 | -8.96 | -6.44 | -8.23 | -1.43 | -0.92 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | -0.00 | -5.06 | -3.30 | -2.10 | 110.07 | -6.72 | -4.05 | |
| EV/EBITDA | 90644.50 | -13.43 | -15.33 | -14.96 | -12.27 | -1.43 | -1.20 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-25.98
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $2.0M | $26.6M | $168.6M |
| Net Income | -$21.6M | -$5.6M | $3.1M |
| EPS | $-0.74 | $-0.19 | $0.06 |
| # Analysts (EPS) | 3 | 3 | 4 |